FindTrial
Sign In

Effects of remifentanil-propofol combined with or without dexmedetomidine on cognitive dysfunction in elder patients after ureteroscopic holmium laser lithotripsy: A prospective randomized controlled trial

Effects of remifentanil-propofol combined with or without dexmedetomidine on cognitive dysfunction in elder patients after ureteroscopic holmium laser lithotripsy: A prospective randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021254
Enrollment
Unknown
Registered
2019-02-03
Start date
2019-01-31
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive function and memory function

Interventions

Group 1:Propofol - rifentanil anesthesia
Group 2:Dexmedetomidine compound Propofol - rifentanil anesthesia

Sponsors

The Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients selected to perform the ureteral holmium laser lithotripsy; aged 60 to 75 years; BMI 20-24.

Exclusion criteria

Exclusion criteria: 1. Adverses response to propofol, remifentanil or dexmedetomidine; 2. Presence of cardiovascular disease, endocrine disease, liver or kidney dysfunctions; 3. Recent smoking, history of chronic use of alcohol; 4. Recent use of sedatives or opioid; 5. Cognitive dysfunction or paracenesthesia and change of surgical.

Design outcomes

Primary

MeasureTime frame
Digital memory;Mini-mental state examination;Zung Self-Rating Depression Scale;State-Trait Anxiety Inventory;—

Countries

China

Contacts

Public ContactFangjun Wang

Affiliated Hospital of North Sichuan Medical College

wfjlxy006@126.com+86 13458253172

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026